Warning
This is an unofficial archive of PsychonautWiki as of 2025-08-08T03:33:20Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.

Coluracetam: Difference between revisions

From PsychonautWiki Archive
Jump to navigation Jump to search
>Josikins
Created page with "{{SubstanceBox/Coluracetam}} {| |- |- | ''Summary sheet: Coluracetam'' |} '''Noopept''' ('''GVS-111''') is a peptide promoted and prescribed in Rus..."
 
>Josikins
Created page with "{{SubstanceBox/Coluracetam}} {| |- |- | ''Summary sheet: Coluracetam'' |} '''Noopept''' ('''GVS-111''') is a peptide promoted and prescribed in Rus..."
(No difference)

Revision as of 02:20, 27 March 2016

Coluracetam
Chemical Nomenclature
Common names Coluracetam
Systematic name N-(2,3-Dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)-2-(2-oxo-1-pyrrolidinyl)acetamide
Class Membership
Psychoactive class Nootropic
Chemical class Racetam
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.



Oral
Dosage
Threshold 1 mg
Light 3 - 5 mg
Common 5 - 10 mg
Strong 10 - 20 mg
Heavy 20 mg +
Duration
Total 3 - 6 hours
Onset 15 - 30 minutes



Insufflated
Dosage
Threshold 1 mg
Light 2 - 5 mg
Common 5 - 10 mg
Strong 10 - 20 mg
Heavy 20 mg +
Duration
Total 3 - 6 hours
Onset 1 - 5 minutes






DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

Interactions
Stimulants
Depressants
Dissociatives
Summary sheet: Coluracetam

Noopept (GVS-111) is a peptide promoted and prescribed in Russia and neighbouring countries as a nootropic with neuroprotective properties. The registered brand name Noopept (Ноопепт) is trademarked by the manufacturer JSC LEKKO Pharmaceuticals. It is readily available and sold through online vendors as a dietary supplement in the U.S. and as a medication in other countries. To supplement noopept, one should take 10 – 30 mg once a day for up to 56 days at a time with extended breaks in between each period of usage.

This compound is growing in popularity because its active dose range is between 10 and 30 mg. This is much smaller than the comparative doses of the racetam class of drugs (piracetam, oxiracetam, phenylpiracetam, etc.)

Chemistry

Noopept, or N-phenylacetyl-L-prolylglycine ethyl ester, is a synthetic peptide. A peptide is a chain of simple amino acids linked by peptide bonds. Noopept contains a phenylacetyl subunit bound to a small peptide chain of proline and glycine. The proline peptide is composed of a carboxylic acid group bound to a pyrrolidine ring at C2. The glycine amino acid is bound to proline with a peptide bond and contains an amino group bond to the free cabon of ethanoic acid. Noopept is structurally similar to the endogenous neuropeptide cycloprolylglycine, for which it is a prodrug of. Noopept is a dipeptide conjugate of piracetam although it is not a racetam as it lacks a pyrrolidone cycle.

Pharmacology

Noopept is not a racetam (due to not having a 2-oxo-pyrrolidine skeleton),[1] but is generally grouped together in the same category because it shares similar mechanisms of action with the racetam family, mainly modulation of the acetylcholine system as well as modulation of AMPA receptors.[2] When compared to traditional racetams, it has been found to be, according to studies, 1000 times more potent than the prototypical racetam drug, piracetam. Noopept is a prodrug for the endogenous peptide cyclopropylglycine.

However, the role of these interactions and how they result in the compound's effects continues to remain elusive.

Subjective effects

The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. The listed effects will rarely (if ever) occur all at once, but heavier dosages will increase the chances and are more likely to induce a full range of effects.

Visual effects

  • Acuity enhancement - Some users have described noopept's visual effects as "widescreen HD vision."
  • Colour enhancement - Noopept has been described to make colours appear more vibrant.

Physical effects

  • Spontaneous tactile sensations - The "body high" which noopept presents can be described as a faint, all-encompassing, soft and consistent tingling sensation.
  • Stimulation - The stimulation which noopept presents can be considered as primarily subtle and encouraged over forceful and distinct.

Cognitive effect

Toxicity and harm potential

There are no known long-term dangers or health safety issues. However, there are a small number of people who suffer from nausea, depression, nervous conditions, tremors, bad mood swings and the inability to sleep. It is recommended to cease usage immediately if these side effects are experienced.

Lethal dosage

The median lethal dosage (LD50) of noopept has not been officially published as it has low abuse potential, but the recommended dosage is 10mg once to three times a day. Anecdotal evidence from people within the community who have tried noopept suggests that there are no negative health effects attributed to simply trying the drug by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption. It is strongly recommended that one use harm reduction practices when using this drug.

Tolerance and addiction potential

There is a slight tolerance with noopept which builds up with repeated usage. There does not seem to be any addictive potential.

This legality section is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

See also

References

  1. The major metabolite of dipeptide piracetam analogue GVS-111 in rat brain and its similarity to endogenous neuropeptide cyclo-L-prolylglycine | http://www.ncbi.nlm.nih.gov/pubmed/9358206/
  2. The original novel nootropic and neuroprotective agent noopept | http://www.ncbi.nlm.nih.gov/pubmed/12596521